The shares of US company Arca Biopharma Inc./ Nuvelo have more than doubled in value Friday 26 March 2010 after the biotechnology company announced that the U.S. Patent and Trademark Office (USPTO) issued a patent on methods of treating heart failure patients with bucindolol (the basis for its Gencaro drug) based on genetic testing.

Bucindolol can be described as a a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic [...]

En savoir plus ? Pour cela, créer GRATUITEMENT votre compte. Dans une seconde, vous pourrez poursuivre votre lecture.
Learn more? If so, create your FREE account. It will take you a second before going back to this paper.

OUVRIR MON COMPTE CREATE MY ACCOUNT

  Un problème avec cet article ? / A problem with this article?